Biomimetics: De-risking the future by borrowing nature’s playbook

Why I believe the next decade of industrial competitiveness will be decided by learning from 4 billion years of R&D, not rhetoric.

Article Featured on Illuminem

Longer-term horizons used to be treated like an upgrade, something valuable, but optional. In the conversations I’m having with boards and C-suites, that mindset is disappearing fast. We’ve entered an era in which the ability to profitably survive over a longer-term horizon than the next few quarters, let alone years, is rapidly becoming the baseline requirement for staying in the game.

When I look closely at the forces reshaping markets from supply chain volatility, regulatory whiplash, shifting customer expectations, to environmental risks that compound rather than reset, then I see a pattern I’ve observed, written about, and even put on a conference about it (CONTEX, 202) across industries: multiple horizons converging at once. That convergence compresses decision windows and punishes fragile or marginal assumptions. If we keep designing industry as if the world is stable and forgiving, and it is built on equilibrium economic models, then the realities of entropy will keep draining our future for that fantasy.

That’s why I believe biomimetics is moving from “interesting” to “strategic.” I don’t see it as a sustainability accessory to add on to a report or a compliance necessity. I see it as a pragmatic economic framework for designing products, materials, and systems that can withstand stresses because those stresses shaped them.

Nature has been running the longest R&D program on Earth. It doesn’t optimize for quarterly optics. It optimizes for durability, frugality, adaptability, and continuity under constraints that include the most work for the least amount of calories and no waste. Net bioeconomic profitability for a specific species in a specific ecosystem. These are precisely the design criteria industry now needs to incorporate as a first principals step.

Chasing innovation versus chasing de-risking

“Innovation” is often framed as a forward-looking bet: invest, experiment, hope it works. But in most industrial contexts, hope is not a method nor a strategy. The next decade won’t reward novelty that increases operational uncertainty. It will reward advances that remove uncertainty using materials that don’t fail, processes that don’t poison, systems that don’t snap when a single link breaks (e.g, relying on supply chains versus building possibility networks). That is why I view biomimetics as a de-risking discipline first.

Instead of asking, “What can we invent?”, biomimetics forces a more useful question: What already works in the real world, at scale, under pressure, and why?

When you anchor innovation to survivability, you stop paying for cleverness and start building toward inevitability. You can then begin to engineer solutions that don’t just perform in the lab but hold up in the only place that matters: the real world of the BiosVerse™.

Demand and scarcity drive economic realities

One pattern I trust more than forecasts is that demand, whether real, imagined, or invented, tends to accelerate everything. When a company articulates a specific need because of materials degradation, a safety gap, a packaging liability, a thermal constraint, or a toxicity exposure, then the solution space becomes knowable. And increasingly, that search leads back to biology. The last 60 years have largely been digital; the next 50 will be biological. 

This is the opposite of the old model, where a new technology goes hunting for a problem or achieves a goal. In biomimetics, the problem is the starting point, and the biological analog becomes the blueprint:

• You can start by defining the failure, cost burden, or liability with precision.

• Then look for the biological analog and find where nature already solved a comparable set of constraints or conditions.

• Finally, the real work: translating those principles into something manufacturable, certifiable, and scalable.

When demand leads, then researchers can most often gain clarity or at least direction. Startups stop guessing where the value lives. Capital gets more rational, because the path from problem → solution → adoption becomes visible. That visibility is how confidence gets built not with hype and vaporware, but with proof and traction.

The resilience multiplier: Bio-solutions rarely stay contained

One of the most underappreciated aspects of biomimetics is that a single breakthrough rarely stays in one lane.

When an aerospace team pursues non-toxic flame resistance inspired by biological chemistry, the underlying approach doesn’t remain confined to aerospace. It tends to spill into medical textiles, packaging, buildings, and transportation. That’s the economic benefit of a resilience multiplier at work.

Why does it compound like that? Because biology doesn’t solve problems in isolation. Living systems don’t have the luxury of one-variable optimization. Nature solves for performance, energy efficiency, repairability, and compatibility with the surrounding system, and out of necessity, it does so simultaneously.

In a world literally drowning in unintended consequences, I don’t think that systems-level efficiency is a side benefit. It’s an advantage that shows up in margins, compliance, and continuity.

Why I’m seeing investors take biomimetics more seriously

Capital becomes cautious when the downside becomes unknowable. And today, the downside of legacy materials and processes is becoming more visible, and as everyone is experiencing it is becoming more expensive across regulation, insurance, personal and property injury, community damage, litigation, and reputation.

One quiet strength of biomimetics is that it often inherently removes risk before it accumulates. Nature-inspired materials and methods can reduce operational overhead and avoid the long-tail liabilities that older material choices tend to carry.

In practical terms, biomimetics can translate into:

• Lower disposal and end-of-life burdens, because many bio-inspired approaches align more naturally with circular pathways. Lower content waste streams mean more profitability in the long term. 

• Reduced transportation and storage friction, because nature rewards local optimization and lightweight efficiency.

• Circular compatibility, enabling a shift away from linear extract-produce-discard models that destroy value over time.

• A hedge against commodity swings, because many biomimetic inputs and pathways are abundant, renewable, or less energy-intensive.

• Lower liability profiles, because bio-aligned chemistry often avoids hazardous compounds that are drawing increasing scrutiny and increasingly showing up where they never should. Like microplastics in your brain.

The lesson here is not complicated. After developing and working with cost models for 35 years, some truths have become apparent to me: when you remove steps, toxins, and waste, you remove costs. You also remove the kind of hidden risk that shows up later as “unexpected” write-downs, compliance emergencies, or reputational damage and moral harm.

Why the BiosVerse™ lens matters 

A major mistake I see companies make is treating biomimetics like an aesthetic: “We were inspired by a leaf.” That’s not strategy, coming from my marketeer perspective, that’s just branding.

If biomimetics is going to matter at an industrial scale, it needs discipline, principles, guardrails, and translation rigor so bio-inspired innovation becomes repeatable, measurable, and credible to regulators, customers, and investors.

That’s why I put an extra weight on structured frameworks like the BiosVerse™, stewarded by Biomimetics International. When any organization uses a coherent framework (e.g., like SEMI standards), rooted in ecological alignment and life-friendly chemistry, it builds trust faster internally and externally, mainly because the logic is consistent, evidence-based, and accessible to all employees and stakeholders. 

I don’t treat a BiosVerse™-aligned strategy as “good ethics” but rather as solid engineering and good finance.

A concrete example: decentralized bio-fabrication, a design principle echoed in mycelial networks. Distributed production reduces single points of failure, strengthens local resilience, and lowers systemic exposure to centralized bottlenecks. Yes, it can require upfront investment. But it buys something far more valuable: continuity, community participation, and cost containment. And continuity, community, and cost will be priced at a premium in the next decade.

What to put on the table in any executive conversation

I don’t think biomimetics needs to start as a moonshot for any organization. The smartest entry point is a targeted risk audit that is focused on where fragility, waste, and looming scarcities are already costing you money or will soon.

If I’m advising leadership, these are the questions I push to the surface:

• Where do we have materials risk (toxicity, brittleness, heat, corrosion, failure rates)?

• Where do we have compliance risk (emerging regulation, disclosure pressure, banned substances, EPR/circularity mandates)?

• Where do we have supply risk (scarce inputs, geopolitical chokepoints, commodity exposure)?

• Where do we have end-of-life risk (disposal cost, recyclability limits, customer requirements)?

Then I would select one high-cost, high-liability problem and run a biomimetics translation process against it making sure to let demand lead, letting biology narrow the solution space, and treating manufacturability as a non-negotiable. That’s how biomimetics becomes operational rather than just ‘feel-good ‘inspirational.

Nature doesn’t negotiate

Here’s a more profound truth I keep coming back to: Nature is the ultimate arbiter. It doesn’t care what you think or believe, but it will respond to what we do to it, with it, or for it. 

And as we learn with each flood, fire, hurricane, or drought, Nature doesn’t negotiate. It doesn’t care whether we find its logic convenient. If our products and systems violate what allows living systems to endure, nature will correct the misapplication, miscalculation, or misappropriation. Sometimes slowly, sometimes brutally, but without a doubt, inevitably. Whether that is tomorrow or seven generations from now, there will be consequences. 

Over the last couple of centuries, science has shown us that evolution, or nature’s R&D, doesn’t guess. By default, it tests, refines, discards the fails, and optimally scales what works.

Industry is being pushed into the same discipline, not because it’s fashionable but because it’s becoming necessary as resources diminish and systems collapse. That predictable future context is what continues to move toward us at an ever-faster pace.  Biomimetics is one of the clearest paths I see for turning the coming constraints into advantages by reducing costs through eliminating waste and de-risking the future. Rather than gambling on the idea that the status quo will somehow sustain an incremental future that’s just ‘moving faster’, we must recognize that the world is actually moving in a decidedly different direction at volume and velocity.

In the decade ahead, I don’t believe consideration for a nature-aligned longer-term horizon will remain just a nice-to-have brand attribute. It will become the entry fee for economic well-being. And the countries and companies that recognize this early won’t just adapt to the new reality, they’ll get out in front, strategically evaluate, and design for it, and de-risk their future.